Anti-Myeloma Activity of Akt Inhibition Is Linked to the Activation Status of PI3K/Akt and MEK/ERK Pathway

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Ramakrishnan, Vijay ^a   Kimlinger, Teresa ^a   Haug, Jessica ^a   Painuly, Utkarsh ^a   Wellik, Linda ^a   Halling, Timothy ^a   Rajkumar, S Vincent ^a   Kumar, Shaji ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; DEXAMETHASONE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESISTANCE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; STROMA CELL; UPREGULATION;

APOPTOSIS; BUTADIENES; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMONES; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MAP KINASE SIGNALING SYSTEM; MORPHOLINES; MULTIPLE MYELOMA; MULTIPROTEIN COMPLEXES; NITRILES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TRANSCRIPTIONAL ACTIVATION;

EID: 84869785019     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050005     Document Type: Article

References (52)

1. Rajkumar SV, (2011) Treatment of multiple myeloma. Nat Rev Clin Oncol 8: 479-491.
2. Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, et al. (2012) Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 26: 149-157.
3. Fruman DA, Meyers RE, Cantley LC, (1998) Phosphoinositide kinases. Annu Rev Biochem 67: 481-507.
4. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, et al. (1996) Mechanism of activation of protein kinase B by insulin and IGF-1. Embo J 15: 6541-6551.
5. Kohn AD, Takeuchi F, Roth RA, (1996) Akt, a pleckstrin homology domain containing kinase, is activated primarily by phosphorylation. J Biol Chem 271: 21920-21926.
6. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, et al. (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-868.
7. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G, (1997) Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278: 687-689.
8. Harris TE, Lawrence JC Jr, (2003) TOR signaling. Sci STKE 2003: re15.
9. Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, et al. (2009) Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15: 429-440.
10. Kennedy SG, Kandel ES, Cross TK, Hay N, (1999) Akt/Protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria. Mol Cell Biol 19: 5800-5810.
11. Kulik G, Klippel A, Weber MJ, (1997) Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol 17: 1595-1606.
12. Shaw RJ, Bardeesy N, Manning BD, Lopez L, Kosmatka M, et al. (2004) The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6: 91-99.
13. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, et al. (2004) Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428: 332-337.
14. Long X, Ortiz-Vega S, Lin Y, Avruch J, (2005) Rheb binding to mammalian target of rapamycin (mTOR) is regulated by amino acid sufficiency. J Biol Chem 280: 23433-23436.
15. Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA, et al. (2007) PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 25: 903-915.
16. Sengupta S, Peterson TR, Sabatini DM, (2010) Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell 40: 310-322.
17. Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, et al. (2002) Tuberous sclerosis complex-1 and-2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A 99: 13571-13576.
18. Chang H, Qi XY, Claudio J, Zhuang L, Patterson B, et al. (2006) Analysis of PTEN deletions and mutations in multiple myeloma. Leuk Res 30: 262-265.
19. Ismail SI, Mahmoud IS, Msallam MM, Sughayer MA, (2010) Hotspot mutations of PIK3CA and AKT1 genes are absent in multiple myeloma. Leuk Res 34: 824-826.
20. Hideshima T, Nakamura N, Chauhan D, Anderson KC, (2001) Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 20: 5991-6000.
21. Hu L, Shi Y, Hsu JH, Gera J, Van Ness B, et al. (2003) Downstream effectors of oncogenic ras in multiple myeloma cells. Blood 101: 3126-3135.
22. Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, et al. (2002) Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 21: 5673-5683.
23. Shi Y, Hsu JH, Hu L, Gera J, Lichtenstein A, (2002) Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6. J Biol Chem 277: 15712-15720.
24. Steinbrunn T, Stuhmer T, Gattenlohner S, Rosenwald A, Mottok A, et al. (2011) Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival. Blood 117: 1998-2004.
25. Farag SS, Zhang S, Jansak BS, Wang X, Kraut E, et al. (2009) Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma. Leuk Res 33: 1475-1480.
26. Hresko RC, Mueckler M, (2005) mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem 280: 40406-40416.
27. Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, et al. (2004) The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 166: 213-223.
28. Krett NL, Zell JL, Halgren RG, Pillay S, Traynor AE, et al. (1997) Cyclic adenosine-3′,5′-monophosphate-mediated cytotoxicity in steroid sensitive and resistant myeloma. Clin Cancer Res 3: 1781-1787.
29. Dalton WS, Durie BG, Alberts DS, Gerlach JH, Cress AE, (1986) Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res 46: 5125-5130.
30. Bellamy WT, Dalton WS, Gleason MC, Grogan TM, Trent JM, (1991) Development and characterization of a melphalan-resistant human multiple myeloma cell line. Cancer Res 51: 995-1002.
31. Katagiri S, Yonezawa T, Kuyama J, Kanayama Y, Nishida K, et al. (1985) Two distinct human myeloma cell lines originating from one patient with myeloma. Int J Cancer 36: 241-246.
32. Ramakrishnan V, Ansell S, Haug J, Grote D, Kimlinger T, et al. (2012) MRK003, a gamma-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma. Leukemia 26: 340-348.
33. Ramakrishnan V, Kimlinger T, Haug J, Timm M, Wellik L, et al. (2010) TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells. Am J Hematol 85: 675-686.
34. Ramakrishnan V, Timm M, Haug JL, Kimlinger TK, Wellik LE, et al. (2010) Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. Oncogene 29: 1190-1202.
35. Chou TC, Talalay P, (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
36. Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, et al. (2006) Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 107: 4053-4062.
37. Moreaux J, Legouffe E, Jourdan E, Quittet P, Reme T, et al. (2004) BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 103: 3148-3157.
38. Zoncu R, Efeyan A, Sabatini DM, (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12: 21-35.
39. Baumann P, Schneider L, Mandl-Weber S, Oduncu F, Schmidmaier R, (2012) Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma. Anticancer Drugs 23: 131-138.
40. Cirstea D, Hideshima T, Rodig S, Santo L, Pozzi S, et al. (2010) Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol Cancer Ther 9: 963-975.
41. Hoang B, Frost P, Shi Y, Belanger E, Benavides A, et al. (2010) Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. Blood 116: 4560-4568.
42. Maiso P, Liu Y, Morgan B, Azab AK, Ren P, et al. (2011) Defining the role of TORC1/2 in multiple myeloma. Blood 118: 6860-6870.
43. McMillin DW, Ooi M, Delmore J, Negri J, Hayden P, et al. (2009) Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res 69: 5835-5842.
44. Hideshima T, Catley L, Raje N, Chauhan D, Podar K, et al. (2007) Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol 138: 783-791.
45. Richardson PG, Wolf J, Jakubowiak A, Zonder J, Lonial S, et al. (2011) Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial. J Clin Oncol 29: 4243-4249.
46. Gills JJ, Dennis PA, (2009) Perifosine: update on a novel Akt inhibitor. Curr Oncol Rep 11: 102-110.
47. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, et al. (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118: 3065-3074.
48. Carriere A, Romeo Y, Acosta-Jaquez HA, Moreau J, Bonneil E, et al. (2011) ERK1/2 phosphorylate Raptor to promote Ras-dependent activation of mTOR complex 1 (mTORC1). J Biol Chem 286: 567-577.
49. Hoeflich KP, O'Brien C, Boyd Z, Cavet G, Guerrero S, et al. (2009) In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 15: 4649-4664.
50. Zimmermann S, Moelling K, (1999) Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 286: 1741-1744.
51. Ding Q, Xia W, Liu JC, Yang JY, Lee DF, et al. (2005) Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol Cell 19: 159-170.
52. Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, et al. (2011) AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19: 58-71.